Medicare Rx Formulary Proposal Praised By Medco
This article was originally published in The Pink Sheet Daily
Executive Summary
CMS decisions regarding regions and PBM tools are also endorsed by Medco. Major risk for Part D is the aggressive timeline, CEO tells investors.
You may also be interested in...
Medco Plans National Medicare Rx Presence: At Risk But Invisible
The PBM plans to create "chassis" for health care plans and employers to customize in offering Part D plans in 2006 and beyond. Time will work in Medco's favor, the company says, because many customers are unlikely to be ready with all the elements of a bid by CMS' deadline.
Medco Plans National Medicare Rx Presence: At Risk But Invisible
The PBM plans to create "chassis" for health care plans and employers to customize in offering Part D plans in 2006 and beyond. Time will work in Medco's favor, the company says, because many customers are unlikely to be ready with all the elements of a bid by CMS' deadline.
USP's Finalized Model For Medicare Rx Formularies Retains 146 Drug Groups
Overall, the model guidelines resemble the version proposed by USP in August but include revisions to specific therapeutic categories and pharmacologic classes. Proton pump inhibitors are placed in a separate drug class; SSRIs/SNRIs remain off the formal chart.